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ABSTRACT:
Bckground: Tacrolimus is an immunosuppressive drug used to lower the risk of transplant rejection in individuals after
solid organ or hematopoietic transplantation. Cases of posterior reversible encephalopathy syndrome (PRES) as a
complication of tacrolimus therapy are infrequently documented. The pathogenesis of this phenomenon is not well
understood. Here, we report a case of an 18-year-old female with a history of acute myeloid leukemia that developed
PRES after undergoing an allogeneic stem cell transplant and subsequent immunosuppressive therapy with tacrolimus.
Keywords: Posterior Reversible Encephalopathy Syndrome, PRES, Tacrolimus, Stem Cell Transplant, Graft Versus Host
Disease

INTRODUCTION: Posterior reversible encephalopathy
syndrome (PRES) is a neurological disorder with a wide
variety of clinical presentations and unique radiological
findings mainly reflective of vasogenic edema. It most
commonly involves bilateral parieto-occipital regions of
the brain[1]. PRES presents clinically with acute
neurological findings consisting of encephalopathy,
seizures, visual disturbances, headache, focal
neurological deficits and status epilepticus[1].
Tacrolimus is a calcineurin inhibitor that works by
inhibiting T-lymphocyte activation and suppresses
cellular immunity [2]. Tacrolimus is often utilized for the
prevention of Graft Versus Host Disease (GVHD) in
patients who have received stem cell transplant (SCT)
for hematogenous disorders and malignancies. PRES
associated with Tacrolimus secondary to allogeneic
stem cell transplant is a relatively rare complication
documented in both pediatric and adult patients [3-7].
The exact incidence of PRES due to tacrolimus therapy
is unknown. Hammerstrom et al. reported an incidence
of 1.1% in their retrospective chart review study on
tacrolimus-associated
PRES
in
hematopoietic
allogeneic SCT, whereas Wong et al. reported an
incidence of 1.6% [6,7]. We report the first case of
tacrolimus-associated PRES in an allogeneic
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hematopoietic stem cell transplant patient from
Pakistan.
Case Description
An 18-year-old female with a history of acute myeloid
leukemia (AML) refractory to chemotherapy underwent
an allogeneic hematopoietic SCT that occurred in
December, 2018. She was on cyclophosphamide for
immunosuppression. Her post-transplantation course
was complicated by hemorrhagic cystitis, reactivation
of cytomegalovirus (CMV) infection and mild GVHD.
CMV infection was diagnosed using a Polymerase Chain
Reaction (PCR) which yielded the CMV quantity of
3600 IU/ml. Patient also presented with a urinary tract
infection which the urine culture and sensitivity showed
to be due to an enterococcus species. Valacyclovir and
ciprofloxacin were added for her on-going infections
and her immunosuppressive therapy was switched to
Tacrolimus 1.5mg once daily. On the third day of
Tacrolimus treatment, she developed two episodes of
generalized tonic-clonic seizures which were one hour
apart, lasted for 15 - 20 seconds and were
self-aborted. These episodes were followed by postictal
confusion, visual hallucinations and altered behavior
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compromising of agitation and irritability.

enhancement, as shown by the blue arrows.

On examination, she had a blood pressure of 110/70
mm Hg, a heart rate of 102 per minute, a temperature
of 370C, and a respiratory rate of 18 breaths per
minute. She was drowsy but oriented to place and
person only. She obeyed single-step commands and
had fluent speech. Motor and sensory examinations
were normal. Neck was supple.

A repeat MRI of the brain on follow-up visit (six weeks
after discharge) showed complete resolution of PRES
(Figure 2) along with significant clinical improvement of
her neurological symptoms. She did not experience
recurrence of seizures or altered mental status.

Baseline laboratory investigations were within normal
limits. Magnetic resonance imaging (MRI) of the brain
with gadolinium contrast revealed diffuse subcortical
hyperintense signals in bilateral cerebral hemispheres
in T2/FLAIR sequences without evidence of diffusion
restriction,
susceptibility
signal
or
contrast
enhancement (Figure 1). These findings were
consistent with PRES. Her electroencephalogram (EEG)
showed diffuse theta and delta slowing as well as
intermittent generalized delta bursts.She was given
levetiracetam. Tacrolimus level was 19 ng/mL (normal
range: 5-20 ng/ml). Tacrolimus was removed from the
patient’s medication regimen and she was given
immunosuppresent cellcept(Mycophenolate mofetil). A
6 week follow-up visit and neuro-imaging showed
complete resolution of PRES both clinically and on MRI
with contrast.
Figure 2: Follow-up MRI Brain showing resolution of
diffuse hyperintense signals in bilateral cerebral
hemispheres in T2/FLAIR sequences shown in figure 1.
Discussion:
PRES as a complication of immunosuppressive
tacrolimus therapy after hematopoietic allogeneic SCT
is relatively rare with a few documented cases in the
literature (Table 1). The pathogenesis of PRES includes
failure of the cerebrovascular auto-regulatory function,
endothelial dysfunction and breakdown of the
blood-brain barrier (BBB) all of which lead to
extravasation of brain plasma resulting in interstitial
edema [1]. Hypertension is often associated with PRES
(an average rise of 25% from baseline blood pressure).
The sympathetic nervous system aids in regulating
when it is challenged by hypertension, however, the
posterior parts of the brain are deficient in sympathetic
innervation, rendering these regions more susceptible
to vasogenic edema [3]. Similarly, endothelial injury
leading to PRES is linked with inflammatory conditions
and cytotoxic effects of certain drugs. (1)
Tacrolimus is used as an immunosuppressive therapy
and prophylaxis for GVHD after a hematopoietic SCT [2].
Tacrolimus is known to cause hypertension which is

Figure 1: MRI Brain showing diffuse subcortical
hyperintense signals in bilateral cerebral hemispheres
in T2/FLAIR sequences and T2 hyperintense signals in
bilateral cerebellar hemispheres without evidence of
diffusion
restriction,
susceptibility
signal
or
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strongly linked to PRES. However, our patient was
normotensive throughout her hospital course.
Hypertension is not always present in PRES patients on
immunosuppressive therapy [4, 7]. 15-20% of patients
with PRES are found to be normotensive [3]. GVHD itself
may also be precipitating this condition via endothelial
vascular cell damage [6], including small and medium
vessel diseases 6,8]. Generalized tonic-clonic seizures,
associated with bilateral occipital sharp waves, may be
seen on EEG. Alternatively, PRES in our patient could
also be related to cyclophosphamide treatment which
she received prior to the Tacrolimus therapy. Cases of
cyclophosphamide-associated PRES have also been
reported in literature [9]. Furthermore, it is also worth
addressing that sepsis and infection have also been
previously associated with PRES since the underlying
cytokine-mediated mechanisms that are observed in
sepsis share many similarities with those associated
with PRES – resulting in increased vascular permeability
of the brain vessels and interstitial extravasation of
plasma [9, 10]. Our patient had ongoing infections at
presentation as well which could’ve compounded to
development of PRES.
Treatment of this condition depends on withdrawal of
tacrolimus and supportive management. A significant
resolution of PRES is seen in all cases. However,
Hammerstrom et al. found no difference between three
groups that were either made to stop tacrolimus
entirely, temporarily stopped tacrolimus for 12 days or
made to switch to another immunosuppressant [6].As
the patient was given antiepileptic for seizures initially
now after resolution of symptoms both clinically and
radiologically it has planned to do eeg and considered
antiepileptics tapering. Although PRES is a mild and
reversible condition, occasionally with inadequate
management the condition proves to be irreversible
and can proceed to coma or death [3, 9]. The mortality
rate associated with PRES is 3-6% [3].
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Conclusion
Tacrolimus-associated PRES in hematopoietic stem cell
transplant patients is an uncommon but serious
complication that requires efficient and timely
management. PRES should be considered as a
possible cause of any neurological symptoms arising in
a patient receiving tacrolimus, even with controlled
blood pressure and normal serum Tacrolimus levels.
Other contributing factors could include GVHD and
infections associated with an immunosuppressed
state. For the resolution of PRES, tacrolimus should be
immediately withheld and supportive treatments should
be provided for other precipitating factors.
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